180 Life Sciences Corp. Files S-1/A Amendment
Ticker: FRMM · Form: S-1/A · Filed: Dec 23, 2024 · CIK: 1690080
Sentiment: neutral
Topics: filing, amendment, corporate-info
TL;DR
180 Life Sciences Corp. (formerly KBL Merger Corp. IV) filed an S-1/A amendment on 12/23/24. Details on their biz.
AI Summary
180 Life Sciences Corp. filed an S-1/A amendment on December 23, 2024, for its registration statement. The company, formerly known as KBL Merger Corp. IV until November 15, 2016, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA 94306.
Why It Matters
This filing indicates ongoing regulatory activity for 180 Life Sciences Corp., which could signal upcoming corporate actions or financial disclosures relevant to investors.
Risk Assessment
Risk Level: medium — S-1/A filings often relate to capital raises or significant corporate changes, which inherently carry risk for investors.
Key Numbers
- 333-280912 — SEC File Number (Identifies the specific registration statement)
- 2834 — SIC Code (Indicates industry classification (Pharmaceutical Preparations))
Key Players & Entities
- 180 Life Sciences Corp. (company) — Registrant
- KBL MERGER CORP. IV (company) — Former company name
- December 23, 2024 (date) — Filing date
- November 15, 2016 (date) — Date of name change
- 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA 94306 (address) — Principal executive offices
- Blair Jordan (person) — Interim Chief Executive Officer
FAQ
What is the purpose of this S-1/A filing?
This is an amendment to a registration statement filed under the Securities Act of 1933, indicating updates or changes to previously submitted information.
When was 180 Life Sciences Corp. previously known by another name?
The company was formerly known as KBL Merger Corp. IV, with the name change occurring on November 15, 2016.
Where are 180 Life Sciences Corp.'s principal executive offices located?
The principal executive offices are located at 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA 94306.
What is the Standard Industrial Classification (SIC) code for 180 Life Sciences Corp.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Who is the Interim Chief Executive Officer of 180 Life Sciences Corp.?
Mr. Blair Jordan is the Interim Chief Executive Officer.
Filing Stats: 4,560 words · 18 min read · ~15 pages · Grade level 17.1 · Accepted 2024-12-23 17:20:53
Key Financial Figures
- $1.74 — stock, at an assumed offering price of $1.74 per unit, which is equal to the closing
- $10,000,000 — r 18, 2024, for gross proceeds of up to $10,000,000. The actual public offering price will
- $0 — d to the public in this offering, minus $0.0001, and the exercise price of each pr
- $0.0001 — ncluded in the pre-funded units will be $0.0001 per share. The pre-funded warrants will
Filing Documents
- ea0225313-s1a2_180life.htm (S-1/A) — 736KB
- ea022531301ex23-1_180life.htm (EX-23.1) — 3KB
- ea022531301ex-fee_180life.htm (EX-FILING FEES) — 23KB
- image_001.jpg (GRAPHIC) — 13KB
- 0001213900-24-112027.txt ( ) — 782KB
Risk Factors
Risk Factors 18 Incorporation by Reference 39
Use of Proceeds
Use of Proceeds 40 Capitalization 42
Dilution
Dilution 44 Dividend Policy 46 Plan of Distribution 47
Description of Capital Stock
Description of Capital Stock 53
Description of Securities We Are Offering
Description of Securities We Are Offering 57 Legal Matters 61 Experts 61 Where You Can Find More Information 61 i Our logo and some of our trademarks and tradenames are used in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property of others. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus may appear without the ®, ™ and SM symbols. References to our trademarks, tradenames and service marks are not intended to indicate in any way that we will not assert to the fullest extent under applicable law our rights or the rights of the applicable licensors if any, nor that respective owners to other intellectual property rights will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. The market data and certain other statistical information used throughout this prospectus are based on independent industry publications, reports by market research firms or other independent sources that we believe to be reliable sources; however, we have not commissioned any of the market or survey data that is presented in this prospectus. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe these industry publications and third-party research, surveys and studies are reliable, provided that we have not commissioned any such information. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as the